Find a Research Lab

Enter a research interest, principal investigator or keyword

Displaying 1 to 9 of 9 results for antiretroviral therapies

Show: 10 · 20 · 50

  1. 1
  • Ashwin Balagopal Lab

    Research in the Ashwin Balagopal Lab examines innate immunology and hepatic inflammation. Specifically, we explore microbial translocation Kupffer cells in HIV- hepatitis C virus (HCV) coinfection, while also developing in situ liver studies of HIV-HCV pathogenesis. Previous work has focused on antiretroviral therapy, interferon sensitivity and virologic setpoint in HIV/hepatitis C virus coinfected patients.

    Research Areas: antiretroviral therapies, infectious disease, AIDS, HIV, hepatitis C

    Principal Investigator

    Ashwin Balagopal, M.D.

    Department

    Medicine

  • Charles Holmes Lab

    Researchers in the Charles Holmes Lab study large-scale strategies for improving information for public health decision-making and for developing more effective and efficient health care delivery models. This includes working on strategies to expand access to antiretroviral therapies and services aimed at preventing mother-to-child disease transmission, as well as methods to integrate evolving science into public health policy.

    Research Areas: antiretroviral therapies, infectious disease, medical decision making, HIV, public health, tuberculosis

    Principal Investigator

    Charles Holmes, M.D., M.P.H.

    Department

    Medicine

  • Craig W. Hendrix Lab

    Research in the Craig W. Hendrix Lab concentrates on the chemoprevention of HIV infection, clinical pharmacology of antiviral drugs, drug interactions, and oral, topical and injectable HIV microbicide development. Our lab conducts small, intensive sampling studies of PK and PD of drugs for HIV prevention with a focus on developing methods to better understand HIV and drug distribution in the male genital tract, female genital tract and lower gastrointestinal tract. We also support numerous HIV pre-exposure prophylaxis development studies from phase I to phase III, largely as leader of the Pharmacology Core Laboratory of both the Microbicide Trial Network and HIV Prevention Trials Network.

    Research Areas: antiretroviral therapies, infectious disease, HIV, drugs

    Principal Investigator

    Craig W. Hendrix, M.D.

    Department

    Medicine

  • Janet Siliciano Lab

    Research in the Janet Siliciano lab focuses on HIV. Areas of study include CD4-positive T lymphocytes, virus latency and highly active antiretrovirals. We recently explored the challenges of detecting HIV persistence during potentially curative interventions and the multifactorial nature of HIV-1 latency.

    Research Areas: antiretroviral therapies, HIV, T lymphocytes

    Principal Investigator

    Janet Siliciano, Ph.D.

    Department

    Medicine

  • Joseph Cofrancesco Jr. Lab

    Research in the Joseph Cofrancesco Jr. Lab focuses primarily on health care for HIV-positive patients. Our recent studies have explored topics such as HIV antiretroviral treatments, HIV resistance and the long-term complications of HIV treatment. In addition, we are part of the U.S. Fat Redistribution and Metabolism (FRAM) study and have had a long-standing involvement in projects that examine metabolic and fat complications in Thailand.

    Research Areas: antiretroviral therapies, infectious disease, AIDS, disease resistance, metabolism, HIV

    Principal Investigator

    Joseph Cofrancesco, M.D., M.P.H.

    Department

    Medicine

  • Kelly E. Dooley Laboratory

    Research focuses on clinical pharmacology of new anti-tuberculosis regimens with an emphasis on: (1) Phase I clinical trials of new or existing anti-TB drugs including dose escalation trials and studies of drug-drug interactions between anti-TB agents and antiretrovirals to treat HIV; (2) Use of PK/PD analysis and modelling in Phase II tuberculosis clinical treatment trials to determine concentration-effect relationships that will allow for optimization of dosing; and (3) Evaluation of TB and HIV drug concentrations in special populations, such as pregnant women and children; (4) Evaluation of treatment-shortening regimens for drug-sensitive TB and investigational regimens for treatment of multidrug-resistant TB; and (5) Translational work involving novel animal models of cavitary pulmonary TB disease to understand drug distribution in diseased lung.

    Research Areas: anti-infective drugs, antiretroviral therapies, tuberculosis and HIV treatments, HIV, lung disease, pharmacology, tuberculosis

    Lab Website

    Principal Investigator

    Kelly Dooley, M.D., M.P.H., Ph.D.

    Department

    Medicine

  • Richard Moore Lab

    Research interests in the Richard Moore Lab include clinical epidemiology, costs, cost-effectiveness and outcomes of HIV/AIDS. We recently examined whether the effect of delaying antiretroviral therapy initiation in HIV-positive adults is modified by age at entry into care.

    Research Areas: epidemiology, antiretroviral therapies, AIDS, HIV

    Principal Investigator

    Richard Moore, M.D.

    Department

    Medicine

  • Robert Siliciano Laboratory

    Research in the Robert Siliciano Laboratory focuses on HIV and antiretroviral therapy (ART). ART consists of combinations of three drugs that inhibit specific steps in the virus life cycle. Though linked to reduced morbidity and mortality rates, ART is not curative. Through our research related to latently infected cells, we've shown that eradicating HIV-1 infection with ART alone is impossible due to the latent reservoir for HIV-1 in resting CD4+ T cells.

    Our laboratory characterized the different forms of HIV-1 that persist in patients on ART. Currently, we are searching for and evaluating drugs that target the latent reservoir. We are also developing assays that can be used to monitor the elimination of this reservoir. We are also interested in the basic pharmacodynamic principles that explain how antiretroviral drugs work. We have recently discovered why certain classes of antiretroviral drugs are so effective at inhibiting viral replication. We are using this discovery along w...ith experimental and computational approaches to develop improved therapies for HIV-1 infection and to understand and prevent drug resistance. Finally, we are studying the immunology of HIV-1 infection, and in particular, the ability of some patients to control the infection without ART. view more

    Research Areas: antiretroviral therapies, HIV, drugs, pharmacology, drug resistance, T cells

    Principal Investigator

    Robert Siliciano, M.D., Ph.D.

    Department

    Medicine

  • Todd Brown Lab

    The Todd Brown Lab focuses on metabolic, endocrine and skeletal abnormalities in HIV-infected patients, particularly as these factors relate to aging. Our studies take an epidemiologic approach to understanding the occurrence and prevalence of insulin resistance, diabetes, and anthropometric changes in HIV patients and their relationship to antiretroviral treatment.

    Research Areas: antiretroviral therapies, insulin resistance, metabolism, HIV, diabetes, endocrinology, skeletal abnormalities

    Principal Investigator

    Todd Brown, M.D., Ph.D.

    Department

    Medicine

  1. 1